Biblio

Author Title [ Type

] Year

Filters: Author is Solary, Eric [Clear All Filters]

Journal Article

Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, Rameau P, Catelain C, Alfaro A, Edmond V, et al. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023.

Pradeu T, Daignan-Fornier B, Ewald A, Germain P-L, Okasha S, Plutynski A, Benzekry S, Bertolaso M, Bissell M, Brown JS, et al. Reuniting philosophy and science to advance cancer research. Biol Rev Camb Philos Soc. 2023.

Solary E. Macrophage colony-stimulating factor as a weapon against cytomegalovirus. EMBO Mol Med. 2023:e18319.

Mosca M, Hermange G, Tisserand A, Noble RJohn, Marzac C, Marty C, Le Sueur C, Campario H, Vertenoeil G, El-Khoury M, et al. Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. Blood. 2021.

Aid Z, Robert E, Lopez CK, Bourgoin M, Boudia F, Le Mene M, Riviere J, Baille M, Benbarche S, Renou L, et al. High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia. Leukemia. 2022.

Saliba J, Hamidi S, Lenglet G, Langlois T, Yin J, Cabagnols X, Secardin L, Legrand C, Galy A, Opolon P, et al. Heterozygous and Homozygous JAK2(V617F) States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. PLoS One. 2013;8(9):e74257.

Itzykson R, Santini V, Thépot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol. 2022:JCO2200437.

Abdelouahab H, Zhang Y, Wittner M, Oishi S, Fujii N, Besancenot R, Plo I, Ribrag V, Solary E, Vainchenker W, et al. CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget. 2016.